A Multi-centre, Multi-national Open-label Sequential Trial Comparing Pharmacokinetics and Safety of N8 and Advate in Subjects With Haemophilia A

Trial Profile

A Multi-centre, Multi-national Open-label Sequential Trial Comparing Pharmacokinetics and Safety of N8 and Advate in Subjects With Haemophilia A

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Turoctocog alfa (Primary) ; Rurioctocog alfa
  • Indications Haemophilia A
  • Focus Pharmacokinetics; Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 02 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top